Fig. 2
From: Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study
Plasma suPAR concentrations (total population). legend: Plasma concentrations of soluble urokinase-type plasminogen activator receptor (suPAR) across the study population. Panel (A) displays suPAR levels for all participants with at least one eligible blood sample (purple). Panel (B) distinguishes between erenumab responders (≥ 50% reduction in monthly migraine days [MMDs], red) and non-responders (< 50% reduction in MMDs, orange). Healthy controls (HCs) are indicated in blue. Box plots represent the median (bold horizontal line) and interquartile range (IQR; top and bottom of the box), with whiskers extending to 1.5 times the IQR. Mean plasma suPAR levels are connected by dots. Statistically significant pairwise differences (p < 0.05) are denoted by dark blue brackets (Supplementary Table S8)